HYL001

HYL001: sourced facts only. name: "Here, we report the synthesis and characterization of HYL001, a potent inhibitor of TGFβ receptor 1 (ALK5), that is approximately 9 times more efficacious than the structurally related compound galunisertib, while maintaining a favorable safety profile." [1] target: "HYL001, a potent inhibitor of TGFβ receptor 1 (ALK5)" [1] developer: "Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 10, Barcelona 08028, Spain." [1] stage: "HYL001 in combination with immune checkpoint blockade (anti-PD1) eradicates liver metastases generated in mice by microsatellite stable, aggressive colorectal cancer tumors at doses where galunisertib is ineffective." [1] modality: "that is approximately 9 times more efficacious than the structurally related compound galunisertib" [1]